Healthy Clinical Trial
Official title:
Capsaicin-induced Muscle Pain in Humans: From Investigating Central Pain Processing to Developing Clinical Applications
There is currently no specific diagnostic test for primary muscular pain. The present study
investigates whether selective blockade of the suprascapular nerve can effectively abolish
experimental pain arising from the supraspinatus muscle. Experimental muscle pain is induced
by intramuscular injection of capsaicin, an alkaloid from red chili peppers. The study
consists of three parts:
1. to describe the development, time course and intensity of capsaicin-induced muscle pain
2. to evaluate the effectiveness of suprascapular nerve block against capsaicin-induced
muscle pain
3. to compare suprascapular nerve block and direct intramuscular local anesthetic
infiltration for their effectiveness in capsaicin-induced muscle pain
Background
Musculoskeletal pain is one of the most common reasons for consulting a physician. Many
musculoskeletal pain disorders are associated with a widespread decrease in pain thresholds,
indicating a state of hyperexcitability of the central nervous system.
This central hypersensitivity can be assessed by measuring pain thresholds to different
experimental stimuli, using so-called quantitative sensory tests (QST).
Several experimental pain models are being used in healthy volunteers in order to study the
central mechanisms of pain processing. Injection of capsaicin is one of them, which is
associated with spreading of local pain, development of referred pain and hyperalgesia to
thermal, mechanical or electrical stimuli.
Intramuscular injection of capsaicin is therefore potentially interesting for investigating
primary muscle pain, central hypersensitivity and endogenous pain modulation. The present
research project comprises three substudies which use intramuscular capsaicin to detect
changes in central pain processing and to evaluate clinical tools for the diagnosis of
primary muscle pain.
Part 1: The investigators hypothesize that the intensity, duration and expansion area of
capsaicin-induced muscle pain depends on a subject's endogenous pain modulation. The
investigators expect that subjects with strong endogenous pain modulation develop less pain
and hyperalgesia after capsaicin injection than subjects with poor endogenous pain
modulation. A large sample of healthy volunteers will therefore be screened using QST and
then recruited for capsaicin injection if they show either very strong or very weak
endogenous pain modulation. The data of the whole sample can be used to determine normative
values of endogenous pain modulation.
Part 2 investigates the ability of suprascapular nerve block to abolish primary muscle pain.
Healthy volunteers will receive capsaicin injection into the supraspinatus muscle or the
trapezius muscle as a control condition in a randomized, blinded fashion. The investigators
expect that the nerve block is more effective in the former compared to the latter muscle.
Part 3 compares the analgesic efficacy of suprascapular nerve block and direct intramuscular
local anesthetic infiltration of the supraspinatus muscle after capsaicin injection. This
will determine which procedure is more effective to treat primary muscle pain.
Objective
1. To determine normative values for endogenous pain modulation in healthy volunteers
2. To demonstrate that capsaicin-induced pain and hyperalgesia depend on endogenous pain
modulation
3. To calculate sensitivity and specificity of suprascapular nerve block for the diagnosis
of primary muscle pain
4. To determine whether suprascapular nerve block or intramuscular local anesthetic
infiltration are more effective against muscle pain
Methods
1. intramuscular injection of capsaicin
2. quantitative sensory tests (pressure pain thresholds)
3. ultrasound-guided suprascapular nerve block
4. ultrasound-guided intramuscular local anesthetic infiltration
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |